The Gleason score is the best independent predictor of prostate cancer outcomes.1 The principle distinction between Gleason 6 disease vs Gleason 7 to 10 disease is that Gleason 6 disease does not necessarily need definitive treatment.2 Nevertheless, the implications of Gleason score are less clear in black men because of disparate prostate cancer outcomes, particularly for Gleason 6 disease, in which risk assessment and management of disease in black men is controversial.2,3 We investigated prostate cancer–specific mortality by Gleason score and race.
Mahal BA, Berman RA, Taplin M, Huang FW. Prostate Cancer–Specific Mortality Across Gleason Scores in Black vs Nonblack Men. JAMA. 2018;320(23):2479–2481. doi:10.1001/jama.2018.11716
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: